Search

…zone are non-competitive antibody. So they’re not competing with the one on the spot. And the one in the red zone, or pinkish red zone, are the one which is…

…still don’t know if there’s any commercial interest in them, but we’re certainly happy to think about commercializing these antibodies. We’re in the process of testing sequences and escape mutants…

…City, Boston, Manchester, England, and Munich, Germany. Carterra products are available in Asia-Pacific and Oceania through our exclusive distributor, Revvity. To learn more, visit www.carterra-bio.com or connect with us on…

…in a complex matrix is also now best-in-class. “We’re proud to see the benefit of Carterra’s LSA platform being brought to bear for global good,” says Tim Germann, Chief Commercial…

…entitled, The therapeutic antibody revolution in the post genomics era. Leading industry experts from some of the most influential pharmaceutical, biotech companies, and institutions in the world such as Bristol…

…You can connect with him for questions about the episode at https://www.linkedin.com/in/timgermann/ or email him at tgermann@carterra-bio.com. Carterra is a privately-held biotech company in Salt Lake City that spun out…

…platform companies. As CEO of ForteBio, Inc., he established product development and commercial strategies that resulted in its rapid growth and acquisition by Pall Corporation. During his nine-year tenure as…

…by artefactual complexity introduced by poor assay design or poorly behaved antibodies. Furthermore, epitope competition is not always a binary process of block or not block, and should instead be…

Carterra® is a leading provider of innovative technologies designed to accelerate the discovery of novel therapeutic candidates. Carterra’s high throughput screening and characterization technology combines patented microfluidics with real-time High…